The nurse is educating a patient newly prescribed empagliflozin when to notify a healthcare provider (HCP). What statement by the client indicates there is a need for further education?

A. If I test positive for glucose in my urine: Empagliflozin, an SGLT2 inhibitor, works by increasing urinary glucose excretion to lower blood glucose levels. Glucosuria is an expected therapeutic effect, so notifying the HCP for this finding is unnecessary. B. If I urinate often and it burns when I go: Burning with urination and urinary frequency can indicate a urinary tract infection, which is a known adverse effect of empagliflozin. Clients should notify their HCP promptly if these symptoms occur. C. If I have genital itching with a white discharge: Empagliflozin increases the risk of genital yeast infections due to glycosuria. Genital itching and discharge require medical evaluation, so this is an appropriate time to contact the HCP. D. If I am urinating less, gaining weight, and my rings feel tight: These are signs of fluid retention and possible kidney complications. Because empagliflozin can affect renal function, this warrants prompt notification of the HCP.